Clinical Evidence
Study One
Gelclair®: potentially an efficacious treatment for chemotherapy-induced mucositis
De Cordi D, Martina S.
Presented at the Third Italian Anti-Tumour League Congress for Professional Oncology Nurses,
Conegliano, Italy, 10-12 October 2001.
Conegliano, Italy, 10-12 October 2001.
Study Outline
Thirty patients with chemotherapy-induced oral mucositis were evaluated for pain, functionality (ability to eat and drink) and grade of oral mucositis, at baseline, 1 day and 3 days after taking Gelclair®
Results
- Pain: 83% reported a reduction in pain, 13% remained the same and 3% showed initial improvement but then got worse.
- Ability to eat and drink: 83% showed distinct improvement, 7% remained the same, 7% got worse, while 3% considerable improvement followed by slight worsening.
- Grade of mucositis: 57% improved, 40% remained the same, 3% got worse.
Patients' Response
Reporting of side effects
Medical device adverse incidents should be reported to the MHRA. Reporting information can be found at https://yellowcard.mhra.gov.uk/. Any adverse event should also be reported to Pharmacovigilance at Alliance Pharmaceuticals Limited
Tel: 01249 466 966 or email: [email protected]
